Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Low Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06966700
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Who this might be right for
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC 2,400
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07466303
What this trial is testing

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

Who this might be right for
Breast CancerSerplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Xijing Hospital 84
Testing effectiveness (Phase 2)Looking for participantsNCT06832202
What this trial is testing

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
HER2-low Hormone Receptor Positive Breast Cancer
Shanghai Henlius Biotech 50
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Early research (Phase 1)Study completedNCT04147819
What this trial is testing

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Who this might be right for
Cancers With HER2 Expression
Bayer 14
Testing effectiveness (Phase 2)Looking for participantsNCT07497386
What this trial is testing

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Who this might be right for
Unresectable Locally Recurrent Breast CancerUnresectable Locally Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 150
Not applicableLooking for participantsNCT07630402
What this trial is testing

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

Who this might be right for
Breast Cancer With Low to Intermediate HER2 Expression
University of Rochester 20
Not applicableLooking for participantsNCT06706557
What this trial is testing

Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
European Institute of Oncology 30
Testing effectiveness (Phase 2)Study completedNCT02491892
What this trial is testing

Pertuzumab in Participants With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 79
Early research (Phase 1)Active Not RecruitingNCT04556773
What this trial is testing

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 138
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07619365
What this trial is testing

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer
Washington University School of Medicine 60
Testing effectiveness (Phase 2)UnknownNCT05726175
What this trial is testing

Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer

Who this might be right for
Breast Cancer
West China Hospital 20
Not applicableNot Yet RecruitingNCT07689929
What this trial is testing

Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 900
Not applicableStudy completedNCT04807595
What this trial is testing

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Who this might be right for
Breast Cancer
AstraZeneca 798
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07772245
What this trial is testing

Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer

Who this might be right for
HER2-addicted Breast Cancer
Polly A. Niravath, MD 30
Not applicableStudy completedNCT06131424
What this trial is testing

NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients

Who this might be right for
HER2-negative
AstraZeneca 1,151
Large-scale testing (Phase 3)Looking for participantsNCT06926868
What this trial is testing

Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Who this might be right for
Breast Neoplasms
Bristol-Myers Squibb 600
Not applicableStudy completedNCT06125314
What this trial is testing

HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

Who this might be right for
Breast NeoplasmsBreast CancerBreast Carcinoma+2 more
AstraZeneca 517
Testing effectiveness (Phase 2)Looking for participantsNCT06298084
What this trial is testing

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Who this might be right for
Breast Cancer MetastaticHER2-positive Metastatic Breast CancerHER2 Low Breast Carcinoma+1 more
Gustave Roussy, Cancer Campus, Grand Paris 152
Testing effectiveness (Phase 2)Looking for participantsNCT06176534
What this trial is testing

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

Who this might be right for
Advanced Breast CancerTreatmentHR Low/HER2 Negative
Henan Cancer Hospital 240
Next Page